Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.

MLA

Furuichi, Nozomi, et al. “Three Cases of Immune-Related Hypopituitarism after Atezolizumab-Bevacizumab Treatment for Hepatocellular Carcinoma.” Clinical Journal of Gastroenterology, vol. 16, no. 3, June 2023, pp. 422–31. EBSCOhost, https://doi.org/10.1007/s12328-023-01775-0.

APA

Furuichi, N., Naganuma, A., Kaburagi, T., Suzuki, Y., Hoshino, T., Shibusawa, N., Horiguchi, S., Hatanaka, T., Kakizaki, S., & Uraoka, T. (2023). Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 16(3), 422–431. https://doi.org/10.1007/s12328-023-01775-0

Chicago

Furuichi, Nozomi, Atsushi Naganuma, Takuya Kaburagi, Yuhei Suzuki, Takashi Hoshino, Nobuyuki Shibusawa, Suguru Horiguchi, Takeshi Hatanaka, Satoru Kakizaki, and Toshio Uraoka. 2023. “Three Cases of Immune-Related Hypopituitarism after Atezolizumab-Bevacizumab Treatment for Hepatocellular Carcinoma.” Clinical Journal of Gastroenterology 16 (3): 422–31. doi:10.1007/s12328-023-01775-0.